Small-molecule targeted drugs compete in the top 10 with Zhengda Tianqing and Hengrui

Inventory: 2019 domestic small molecules targeted drug marketwith the rapid development of China's large health industry, as well as the demand for precision medicine is changing with each passing dayUnder the influence of the trend of aging market in Chinese, many factors make the demand demand of the drug market increase day by day, and promote the growth of the drug market under the impetus of the targeted drug markettargeted drugs are composed of bioengineered monoclonal antibody drugs and chemical small molecule-targeted drugs, especially small-molecule targeted drugs with the characteristics of easy to use drugs, strong compliance, in the anti-tumor and incurable diseases drug market has attracted attentionAccording to minet data, china's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public health institutions) have reached 149.944 billion yuan in anti-tumor and immunomodulatory drugs in 2019, an increase of 14.20% year-on-year, and China's urban public hospitals have become the main consumer terminals in the anti-tumor and immunomodulator marketwell known, targeted drugs are one of the first choice for precision medicine in ChinaAccording to statistics, more than 50 small molecule-targeted drugs have been approved in China, including the independently developed 1 class of small molecule-targeting drugs are Ektini (Cameina), Hengrui Pharmaceuticals' Apatini (Etan) and Quiridini (Erini), Hutchison Whampoa Seven innovative drugs, such as the furanitinib (Eyot), the positive and sunny Anrotinib (Fucovi), the nilapali (Sele) of Reding Pharmaceuticals, and the metasulinic ametinib (amel) of Jiangsu Haussen Pharmaceuticalsmeters net data show that in 2019, the clinical use of small molecule-targeted drugs in public hospitals in key provinces and cities in China has exceeded 50 chemical varieties, sales reached 12 billion yuan, an increase of 31.04 percent year-on-year, two consecutive years of growth of more than 30 percentOxitini EGFR-TKI targets a uniquein recent years, key provincial and municipal public hospitals newly listed small molecule target drug TOP10 varieties (units: million yuan)meters of intranet data show that after 2017, into the key provinces and cities of public hospitals, small molecules targeted drugs have 21 drugs, of which small molecule target drugs TOP10 sales of 2.351 billion yuan, a year-on-year growth rate of 1268.41 percentThe first drug is OsimertinibOxitini is the drug named Tagrisso, which was approved by the FDA in November 2015In March 2017, the State Drug Administration approved the registration of the commodity name TerishaIt is suitable for the treatment of advanced disease during or after treatment of pastepider growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), and the treatment of adult patients with advanced localized or metastatic non-small cell lung cancer (NSCLC) with positive EGFR T790M mutation has been detected2019, Theositini's global market reached $3.189 billion, up 71.45 percent year-on-year, making it a leading astral and accounting for one-third of AstraZeneca's anti-tumor targeting drug sectorAccording to the data of Minet, sales of Oshitini (Terissa) in key provinces and cities in China reached 948 million yuan in 2019, up 40.14% year-on-year Oxitinib is the preferred treatment for Patients with T790M-positive NSCLC, and in September 2018, the National Health Insurance Administration was included in the health insurance list After 17 cancer drugs were included in the category B coverage, the average decrease was 56.7% In particular, Oxitinib decreased by 71%, from the previous 528,000 yuan / box / month to 153,000 yuan / box / month, improve the patient's drug use, objectively promoted the rapid growth of Terisa Anrotini capsule growth of 1854.59 percent Anrotini is the independent brand developed by Zhengda Tianqing Pharmaceutical Group, target VEGFR, for China's late NSCLC third-line treatment provides a new choice On May 8, 2018, it was approved for the market by the State Drug Administration, and the product was named Fuweiwei After negotiations, Anrotini reduced the price by 45% and was successfully included in the National Class B Health Insurance List at a price of 487 yuan per grain (12 mg) meters net data show that in 2019, the domestic key provinces and cities of public hospitals Arottini (Fucovi) sales of 614 million yuan, an increase of 1854.59 percent year-on-year It is reported that Anrotinib in other cancers to carry out clinical research, including small cell lung cancer, soft tissue sarcoma, esophageal squamous cancer, thyroid cancer and kidney cancer, have obtained good clinical data results, will become the release of Focovi's potential in the market to provide new hope Imateni is a 3 billion-dollar domestic imateinib is a tyrosine kinase inhibitor drug developed by Novartis On May 10, 2001, Imatinib received the FDA's express approval for "breakthrough anti-tumor mechanism" under the name "Gleevec" Global Novartis's Greeve sales still reached $1.263 billion in 2019, down 19.09 percent from a year earlier, after sales of more than $70 billion in 2019 imartinib for the treatment of chronic patients with chronic stage serotic disease, acceleration period or alpha-interferon treatment failure; After the expiration of the patent, domestic imitations have been developed and listed In 2013, Jiangsu Howsen Pharmaceutical Group Imatini film listed, the commodity name Wei In 2014, Itwasani capsules were listed by Zhengda Tianqing Pharmaceutical Group, with the product name Gnico, followed by imatinib tablets of stone pharmaceutical group, and the commodity name Nolinin with the "4 plus 7" collection of the promotion, Jiangsu Howson produced 100mg x 12 tablets / plate s 1 board / bag x 5 bags (60 tablets) specifications of the generic drug memartini, the winning price of 623.82 yuan meters net data show that in 2019, the domestic key provinces and cities public sample hospital Samartini market of 695 million yuan, in the situation of volume-for-value situation, down 15.73 percent year-on-year, still in the small molecule targeted drugs sales of the third-largest variety 2019, Novartis's Grewe accounted for 76.10%, down 3.4 percentage points, Jiangsu Howson's Weiwei accounted for 17.76 percent, up 5.9 percentage points, Zhengda Tian's Ginico accounted for 5.26 percent, and The Stone Pharmaceutical O'Leary's Nollin in 0.89 percent in recent years, more than a new batch of small molecule target drugs 2018 NMPA approved the listing of small molecule target new drugs
the State Drug Administration in 2018 approved 10 new small molecule target drugs, in 2019 approved 8 new small molecule target drugs In 2020, the global outbreak of new coronary pneumonia, the National Drug Administration Drug Review Center continues to open the green channel, the new approval of Jiangsu Howson Pharmaceuticals of the sulfonate amitinib, the United States Puma Biotechnology, Inc.'s Malayacid nalatinib tablets, Novartis Pharmaceuticals of Switzerland's Sinimod tablets, Teva Pharmaceuticals' niobium beninatablets 2019-May 2020 NMPA approved the listing of small molecules target new drugs meters intranet data show that in 2019 the domestic key provinces and cities of public sample hospital target drug market of nearly 20 billion yuan market size, an increase of 32.88 percent year-on-year, of which antibody-targeted drugs accounted for 40%, small molecule targeted drug use market accounted for 60%.